曲拉西利合成路线图解  

Graphical synthetic routes to trilaciclib

作　　者：张茂风 王立中[1] 刘竺云[1] 沈玉凤 ZHANG Mao-feng;WANG Li-zhong;LIU Zhu-yun;SHEN Yu-feng

机构地区：[1]泰州职业技术学院药学院,江苏泰州225300 [2]江苏省固体制剂工程技术研究开发中心,江苏泰州225300

出　　处：《中国药物化学杂志》2022年第4期330-334,共5页Chinese Journal of Medicinal Chemistry

基　　金：江苏省自然科学基金项目(BK20190246);江苏省高等学校自然科学研究项目(19KJB350011)。

摘　　要：曲拉西利(trilaciclib,G1T28),又名美法仑氟芬胺,化学名称为2′-{[5-(4-甲基哌嗪-1-基)吡啶-2-基]氨基}-7′,8′-二氢-6′H-螺[环己烷-1,9′-吡嗪并[1′,2′:1,5]吡咯并[2,3-d]嘧啶]-6′-酮,分子式:C24H30N8O,分子量:446.56,CAS登记号:1374743-00-6。曲拉西利商品名为Cosela[1-2],由G1 Therapeutics公司开发.Trilaciclib was a CDK 4/6 reversible inhibitor.It was mainly used to prevent bone marrow suppression caused by chemotherapy in adult patients with diffuse small cell lung cancer.Four representative synthetic routes of trilaciclib and the key intermediates herein were summarized.By analyzing the advantages and disadvantages of different routes,the suitable synthetic route was recommended to provide guidance for further industrial production.

关 键 词：美法仑 合成路线图解 登记号 氟芬 

分 类 号：R914[医药卫生—药物化学]